Pages that link to "Q54069308"
Jump to navigation
Jump to search
The following pages link to Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. (Q54069308):
Displaying 50 items.
- Structure of the catalytic domain ofStreptococcus pneumoniaesialidase NanA (Q27651923) (← links)
- Using hospital antibiogram data to assess regional pneumococcal resistance to antibiotics (Q30772203) (← links)
- Prevalence of beta-lactamase production in H. influenzae isolated in Latin America in 1998-1999: results of the LASER study. (Q30830039) (← links)
- Antimicrobial Resistance among Isolates of Respiratory Tract Infection Pathogens from the Southern United States: Data from the PROTEKT US Surveillance Program 2000/2001 (Q30882602) (← links)
- Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. (Q30885891) (← links)
- Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition (Q32039109) (← links)
- Moraxella catarrhalis: from emerging to established pathogen (Q33906182) (← links)
- Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States (Q33980574) (← links)
- Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States (Q33980689) (← links)
- In vitro and In vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogens (Q33980926) (← links)
- Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance (Q33981224) (← links)
- Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis (Q33981832) (← links)
- Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae (Q33982211) (← links)
- New approaches in the treatment of bacterial infections (Q34014372) (← links)
- Longitudinal assessment of antipneumococcal susceptibility in the United States (Q34110932) (← links)
- Evaluation of the clinical microbiology profile of moxifloxacin (Q34183540) (← links)
- Infections in multiple myeloma (Q34305052) (← links)
- Development and spread of bacterial resistance to antimicrobial agents: an overview. (Q34347837) (← links)
- Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States (Q34347889) (← links)
- Infectious morbidity in critically ill patients with cancer (Q34348047) (← links)
- The clinical impact of macrolide resistance in pneumococcal respiratory infections (Q34382806) (← links)
- Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance (Q34502866) (← links)
- Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain (Q34521482) (← links)
- Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections (Q34621459) (← links)
- Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA. (Q34635690) (← links)
- Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children (Q34756483) (← links)
- Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models (Q35201049) (← links)
- Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year (Q35590537) (← links)
- Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections (Q35627730) (← links)
- Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance (Q35692693) (← links)
- Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update (Q35951616) (← links)
- Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection (Q36338182) (← links)
- Randomized Clinical Trial of a Sustained-Exposure Ciprofloxacin for Intratympanic Injection During Tympanostomy Tube Surgery (Q36449852) (← links)
- Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. (Q36770336) (← links)
- In vitro activities of piperacillin against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae (Q37119929) (← links)
- Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates. (Q37703447) (← links)
- Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (Q39651279) (← links)
- In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations (Q39746806) (← links)
- Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States (Q39755545) (← links)
- Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor (Q39792503) (← links)
- Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials (Q40711748) (← links)
- Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study (Q40756323) (← links)
- Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer (Q42605189) (← links)
- Relationship between antibiotic resistance in Streptococcus pneumoniae and that in Haemophilus influenzae: evidence for common selective pressure (Q42781871) (← links)
- Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland (Q43476877) (← links)
- In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics (Q43585614) (← links)
- Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae (Q43597722) (← links)
- In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens (Q43670525) (← links)
- Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina (Q43750726) (← links)
- Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana (Q43750729) (← links)